Bicycle Therapeutics Enters Exclusive License And Collaboration Agreement With Ionis To Develop Targeted Oligonucleotide Therapeutics; Bicycle To Receive $45M Upfront Payment And Is Eligible For Milestone Payments And Royalties

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!